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Reviewer #1: This paper tested the hypothesis that dogs suffering from OA exhibit signs 
of central sensitization and reduced DNIC. The results showed increased nociceptive 
withdrawal reflex threshold in OA animals, increased EMG response in OA dogs 
receiving NSAID, increased temporal summation in OA dogs, and reduced DNIC in OA 
dogs. There are some concerns on these observations that needs to be addressed. 
 
1. The EMG recording method should be described. The consistency of the recording is 
unclear since errors are not given in figures. 
 
We are unsure as to what additional information about the EMG recording method is 
required by the reviewer. We have provided sufficient detail for the methods to be 
repeated by another research group and have also provided example traces of the EMG 
responses obtained. We would be grateful for further clarification on this point. We 
sought advice from a statistician about how to represent the data most clearly and 
accurately. He advised us that it is technically incorrect to put error bars on a repeated 
measurements graph because the point errors are not constraints on the line. If required 
we could add prediction error lines to the graph (2 per treatment group) but in our 
opinion the addition of 6 extra lines to the graph would decrease clarity. 
 
2. The EMG threshold was higher in the OA group. In Figure 7a, OA animals showed 
smaller response magnitude compared to controls. These results are incomprehensible 
since OA animals should have spontaneous pain with peripheral sensitization. The 
authors have attended this paradox, but the issue is still there. I am not aware of a 
similar observation in the literature. This result would cause confusion in the field and 
should be verified carefully. 
 
We disagree with the statement that peripheral sensitisation would have been present 
at the site of electrical stimulation of the skin of the toes of dogs. Dogs did not have OA 
of their toes, rather they had radiographic signs of OA in their stifles and / or hips. 
Therefore the afferents we were stimulating wouldn’t have been sensitized peripherally 
but the reflex pathway would have been sensitized centrally by the input from the 
arthritic knee / hip joint afferents.  
 
We are confident in our finding that thresholds were lower in control dogs compared to 
dogs with OA; these data were generated from a large number of dogs and variability in 
these data were relatively low. We agree that this is difficult to explain but have 
suggested that it may be due to A beta mediated hypoaesthesia in the OA dogs. In the 
concluding paragraph of the discussion we have also highlighted this paradox and 
emphasized that not all the data collected in this study supported the contention that 
dogs with OA have central sensitization. This finding however should not detract from 
the impact of our studies; what the present data show is that in dogs with central 
sensitisation, electrical thresholds are not a reliable measure to use clinically whereas 
other tests are more robust at differentiating between dogs with central sensitisation and 
healthy control dogs. This conclusion is supported in point 4 raised by reviewer 2. 
Figure 7a was generated from the DNIC data set which involved fewer animals and 
generally the figure has caused some confusion with the reviewers. We have therefore 
Response to Reviewers
chosen to represent the DNIC findings differently and Figure 7 has been replaced by a 
new figure which we hope is clearer. The new Figure shows that suppression of the 
EMG response to the test stimuli by the conditioning mechanical stimulus was greater in 
the control population of animals. 
 
3. Figure 5 shows no difference between control and OA dogs. This is another paradox 
to be explained. 
 
We feel that this can be explained by the fact that OA dogs not receiving daily NSAID 
treatment were likely in less pain than dogs that were receiving daily NSAID treatment 
as shown by the differences in scores in the clinical metrology instruments that were 
used to measure pain in the different groups of dogs (Table 2). Therefore, there was a 
difference in stimulus response curves between the two groups of dogs (OA and 
OANSAID) with OA dogs not being different from control. Central sensitisation therefore 
appeared to be more apparent in the OANSAID group hence a methodology involving 
‘single’ stimuli in the stimulus response curve was effective for detecting CS in this 
group whereas the methodology using trains of stimuli allowed detection of CS in the 
OA group as well – suggesting that the temporal summation/wind up protocol is 
generally better for indicating central sensitisation in OA dogs but that stimulus 
response methodology may be a useful tool for clinically detecting more severe, painful 
OA. 
 
4. Figure 6 shows the same level of temporal summation between OA and OANSAID 
groups. This is in contrast with the authors' claim that OANSAID dogs have more 
intense pain. 
 
Temporal summation is considered to be a biomarker for central sensitization and our 
results suggest that the degree of central sensitization was similar between OA and 
OANSAID groups. However clinical reasoning would support the statement that dogs 
receiving analgesic treatment were more severely impaired than dogs not receiving 
NSAIDs and likely in more intense pain, as would our stimulus response curve data. 
This is supported by the clinical metrology data which showed that (on some scales) 
dogs with OA receiving daily NSAIDs were more severely affected than dogs with OA 
that were not receiving treatment (Table 2). We can explain the paradox that temporal 
summation did not discriminate between the two OA groups of dogs (OA and 
OANSAID) by the fact that the trains of stimuli at 10 mA used in the temporal 
summation protocol were very intense and therefore provoked a response in both 
groups of dogs. In contrast the stimulus response protocol did differentiate between OA 
and OANSAID groups because it used single stimuli to evoke responses. 
 
5. The authors state, control animals demonstrated greater inhibition compared with 
OA. Figure 7 shows that this may not be the case. The pre-DNIC values are different in 
control and OA dogs and the percent reduction of response magnitude during 
conditioned stimulus should be similar between the two groups (Fig. 7c). The pre-DNIC 
values are also different in Fig. 7a and c, d. OA group had lower response magnitude in 
7a but higher pre-DNIC value in 7c,d. In Fig. 7b, the control and OA groups had the 
same pre-DNIC response magnitude. These are confusing and raise question on the 
data consistency. 
 
We have substituted Figure 7 for a new Figure in which the DNIC data are normalized 
to the baseline (pre DNIC responses). This should remove the confusion about relative 
responses in the two groups; these data clearly show that despite variability the 
magnitude of response to the test stimuli is reduced in the control group (DNIC effect) 
while suppression is much less in the OA group with impaired DNIC. 
 
Reviewer #2: This study on the electrophysiological assessments of NWR, TS, and 
DNIC in dogs with and without OA is very interesting. The edits have improved the 
clarity and interpretation of these study results overall. However I still had a few 
questions for the authors: 
 
1. You indicate that you would recruit 100 OA dogs to achieve adequate power, yet you 
have 75 dogs with OA. Was that an error in your power assessment? 
 
As stated in the manuscript, the initial power calculation was based on von Frey data 
rather than EMG outcome measures because no EMG data from dogs with OA were 
available prior to this study. We were anticipating greater heterogeneity in the OA group 
with respect to the presence or absence of central sensitization than we actually found 
(the majority of dogs with OA appeared to show NWR characteristics consistent with 
central sensitization) therefore the study was adequately powered to show statistically 
significant differences between groups. We have also referred this question to a 
Chartered statistician. He has pointed that sample size calculations are not an exact 
science, they require many assumptions, and a number of estimates to be made about 
future, unkown performance in a study. Conservatively, they should be considered an 
indication of the order of magnitude required.  
 
2. You indicate how many dogs are recruited for the DNIC portion in the methods, but 
only in results for the NWR,TS portion of the study? This is inconsistent. 
 
We are sorry for the inconsistency. As all n numbers for each part of the study are 
provided in detail in figure 1, we have moved the direct indication of numbers for the 
DNIC studies from the methods (section 2.14) to the appropriate place in the results 
(section 3.10). So now section 2.14 refers the reader to figure 1 i.e. consistent with the 
rest of the methods, and the results section now clearly indicates how many dogs were 
used for the NWR, TS and DNIC paradigms within the main text. When first referring to 
figure 1 at the end of section 2.2, we have also added ‘…and the subsequent numbers 
that were used at each stage of the study’ to emphasize this is where information on n 
numbers can easily be found. 
 
3. You state you did not perform QST in dogs in your response to R1, but I would argue 
that the NWR and TS are forms of QST. There are many types of quantitative sensory 
testing, not just heat and pressure thresholds.  
 
This is a good point and we are happy to agree that NWR and TS could be considered 
forms of QST. However as we have not made any reference to QST within the 
manuscript, we don’t feel any changes to the text are required. 
 
4. The conclusions state you found CS in dogs with OA, yet your thresholds were 
actually higher in OA dogs, which might be used to suggest the opposite. The addition 
of the sentence indicating this is difficult to understand is helpful, but the omission of this 
conflicting evidence for CS does not bring clarity. It would be helpful to more clearly 
state that several measures are consistent with CS in dogs with OA, but that thresholds 
were not - or something to that effect. 
 
Thank you for this useful comment which we agree with entirely. Although data for 
thresholds did not follow the ‘expected’ trend, this should not detract from our other data 
which strongly supports the presence of central sensitisation in OA dogs – therefore 
rather than seeing threshold data as evidence for a lack of central sensitisation, an 
outcome of these studies is that using the present methodology, it would seem that 
measuring and comparing thresholds is not a suitable parameter for assessing central 
sensitisation. We have added a sentence to this effect in the concluding paragraph of 
the discussion. 
 
5. Thank you for adding the two figures with EMG data; that is very helpful. But I still find 
the logarithmic scale on one figure easy to miss. Possible add parentheses to help 
show that Ln is a function and not just part of the variable name (i.e., Ln (mV..)) or 
clearly mention the logarithm in the legend (i.e., natural logarithm of the response 
magnitude...). 
 
Thank you for this comment – we have made this clear in the figure legends. 
 
 
Reviewer #3: The authors have performed a large study to examine signs of OA-
mediated central sensitization (CS) in dogs. I think that the study is important and 
commend the authors for their work in this important area. I have several comments to 
improve the paper: 
1) The results are written in a very convoluted fashion that could easily be simplified. I 
would strongly encourage the authors to focus on making the work as accessible as 
possible to readers. 
 
We are sorry that you found the results section to be convoluted but we are unsure as 
to how to simplify them further. We think that it is important to report the interactions 
between weight, age and stimulating current as well as the change in temporal 
summation over the three repeats of the train of electrical stimuli. This inevitably makes 
the results more complex to present, but leaving out this information could also be 
misleading for the reader. We found that Figure 7 has caused significant confusion for 
the reviewers and therefore have represented the data in a different way which we hope 
improves clarity. 
 
2) I find the data presentation in the figures to be lacking. The spread of the data simply 
must be represented in some way with error bars. 
 
We sought advice from a statistician about how to represent the data most clearly and 
accurately. He advised us that it is technically incorrect to put error bars on a repeated 
measurements graph because the point errors are not constraints on the line. If required 
we could add prediction error lines to the graph (2 per treatment group) but in our 
opinion the addition of 6 extra lines to the graph would decrease clarity. We leave this 
decision to the editor, but point out that it was not raised as a concern by all reviewers.  
 
3) The authors need to clarify that some of the stimulus parameters where no changes 
are observed are almost certainly Abeta mediated (at least as I understand the 
experimental parameters). 
 
We have added in to the discussion that the lack of differences between groups for the 
temporal summation early response data could be because the early response is largely 
A beta fibre mediated. 
 
4) The interpretation of the data is too heavily weighted toward CS. It is also possible 
that the EMG findings for C-fiber mediated responses are mediated by C fiber 
sensitization and do not require CS. 
 
Thank you for this comment, we have acknowledged this in the discussion, although 
whether the changes in C fiber responses are due to central sensitization or C fibre 
sensitization cannot be discerned from our data set. 
 
 
5) The DNIC findings are very interesting, and significant, but the presentation is 
convoluted and the presentation of the data is very challenging to understand. The 
authors should work to make this clear, and also represent the experimental variation. 
 
We agree that Figure 7 was confusing and have changed this figure to represent the 
findings of the DNIC investigation in a clearer way.  
 
6) The discussion is focused on items that could be clarified in the results. One issue 
that is not touched upon at all, which was very surprising to me, was the increasing 
focus on using companion animals for mechanistic clinical trials to advance therapeutic 
development in humans. This study could be a landmark work in that area as it 
demonstrates very similar findings to what is seen in humans with OA. I think that the 
authors should mention bring this up. 
 
Thank you for this comment. We have added a sentence to this effect in the concluding 
paragraph of the discussion. 
Abstract  
 
In man, central sensitisation (CS) contributes to the pain of osteoarthritis (OA). Dogs with 
spontaneous OA may also exhibit CS. Electrophysiological reflex measurements are more 
objective than behavioural assessments, and can be used to evaluate CS in preclinical and 
clinical studies. It was hypothesised that dogs suffering from OA would exhibit 
electrophysiological characteristics indicative of CS, associated with reduced diffuse noxious 
inhibitory controls (DNIC). 117 client owned dogs were recruited to the study. Hindlimb 
nociceptive withdrawal reflex (NWR) thresholds, stimulus response, and temporal 
summation characteristics were recorded, during alfaxalone anaesthesia, from 46 OA dogs, 
29 OA dogs receiving non-steroidal anti-inflammatory drugs (OANSAID), and 27 breed- and 
weight-matched control dogs. Efficacy of DNIC was evaluated in 12 control and 11 of the 
OA dogs, by application of a mechanical conditioning stimulus to the contralateral forelimb.  
NWR thresholds were higher in OA compared with control dogs (p = 0.02). Stimulus 
response characteristics demonstrated an augmented response in OANSAID dogs compared 
with OA (p < 0.001) and control (p < 0.001) dogs. Temporal summation demonstrated 
exaggerated C-fibre mediated responses in both OA (p < 0.001) and OANSAID (p = 0.005) 
groups, compared with control animals. Conditioning stimulus application resulted in 
inhibition of test reflex responses in both OA and control animals (p < 0.001); control 
animals demonstrated greater inhibition compared with OA (p = 0.0499). These data provide 
evidence of neurophysiological changes consistent with CS in dogs with spontaneous OA, 
and demonstrate that canine OA is associated with reduced DNIC. 
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Abstract  
 
In man, central sensitisation (CS) contributes to the pain of osteoarthritis (OA). Dogs with 
spontaneous OA may also exhibit CS. Electrophysiological reflex measurements are more 
objective than behavioural assessments, and can be used to evaluate CS in preclinical and 
clinical studies. It was hypothesised that dogs suffering from OA would exhibit 
electrophysiological characteristics indicative of CS, associated with reduced diffuse noxious 
inhibitory controls (DNIC). 117 client owned dogs were recruited to the study. Hindlimb 
nociceptive withdrawal reflex (NWR) thresholds, stimulus response, and temporal 
summation characteristics were recorded, during alfaxalone anaesthesia, from 46 OA dogs, 
29 OA dogs receiving non-steroidal anti-inflammatory drugs (OANSAID), and 27 breed- and 
weight-matched control dogs. Efficacy of DNIC was evaluated in 12 control and 11 of the 
OA dogs, by application of a mechanical conditioning stimulus to the contralateral forelimb.  
NWR thresholds were higher in OA compared with control dogs (p = 0.02). Stimulus 
response characteristics demonstrated an augmented response in OANSAID dogs compared 
with OA (p < 0.001) and control (p < 0.001) dogs. Temporal summation demonstrated 
exaggerated C-fibre mediated responses in both OA (p < 0.001) and OANSAID (p = 0.005) 
groups, compared with control animals. Conditioning stimulus application resulted in 
inhibition of test reflex responses in both OA and control animals (p < 0.001); control 
animals demonstrated greater inhibition compared with OA (p = 0.0499). These data provide 
evidence of neurophysiological changes consistent with CS in dogs with spontaneous OA, 
and demonstrate that canine OA is associated with reduced DNIC. 
 
Keywords: Central Sensitisation; Diffuse Noxious Inhibitory Controls; Dog; Nociceptive 
Withdrawal Reflex; Osteoarthritis 
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1. Introduction  
Spontaneous canine osteoarthritis (OA) has been proposed as a model of human OA [39]. In 
man, in addition to mechanisms local to affected joints, central sensitisation (CS) may 
exacerbate pain [30]. Some dogs affected by OA respond to centrally acting antihyperalgesic 
drugs [26] and have altered nociceptive thresholds [21], suggesting CS; however, there is no 
‘gold standard’ approach for identifying and quantifying CS in dogs. Therefore, it is currently 
unknown whether OA in dogs is also associated with CS, yet this information is essential if 
canine OA is to be used as a valid model of human OA.  
 
The RIII withdrawal response threshold and magnitude, and temporal summation (TS) to 
repeated stimuli are altered in pain syndromes associated with CS in man, and may be used as 
objective markers of CS [38]. In dogs, the nociceptive withdrawal reflex (NWR) [6] and TS 
of the NWR [8] have been suggested as potential biomarkers for CS. We have previously 
developed methods to evaluate these measures during anaesthesia [19]. There are, presently, 
no reports of alterations in NWR or TS associated with painful disease in dogs, and the 
potential for the technique to characterise the state of spinal excitability remains untested.  
 
Diffuse noxious inhibitory controls (DNIC) represent an endogenous supraspinal anti-
nociceptive mechanism activated by heterotopic noxious (‘conditioning’) stimulation [5,15]. 
Efficacy of conditioned pain modulation (CPM) in man (considered the equivalent of DNIC) 
is a predictor of acute [14] and chronic post-operative [42] pain, and is commonly reduced in 
chronic pain states, including OA [2]. There are no investigations of DNIC efficacy 
associated with OA in dogs. CPM may be modulated by cognitive influences [31], which are 
challenging to control for experimentally. Therefore, it is desirable to develop a non-tissue 
damaging paradigm, which may be applied to anaesthetised animals.  
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 3 
 
The primary aim of the studies described here was to compare electrophysiological 
responses, including temporal summation of C fibre responses, in a cohort of client owned 
pet dogs suffering spontaneous OA, with a matched group of control pet dogs. Dogs within 
the OA cohort were divided into those receiving daily NSAIDs to manage OA associated 
pain (OANSAID) and dogs not receiving drug treatment (OA). We hypothesised that dogs 
with OA would exhibit electrophysiological characteristics indicative of CS, and that these 
characteristics would be exaggerated in the OANSAID group compared to the OA group 
because of the greater pain that was likely experienced by OANSAID dogs despite ongoing 
NSAID administration.  
Our second aim was to develop an effective protocol to evaluate DNIC in dogs. CPM has 
been elicited by mechanical conditioning stimulation (MCS) [34], therefore we sought to 
investigate whether MCS would evoke DNIC, and whether DNIC efficacy was decreased by 
OA. We hypothesised that in control dogs, application of MCS would inhibit the NWR, and 
that the degree of inhibition would be reduced in dogs affected by OA.  
 
2. Methods 
Part i) NWR/TS investigation 
 
2.1 Ethics 
The study was conducted under the terms of the Animal (Scientific Procedures) Act, 1986 (as 
amended, 2013) (A(SP)A) licence number PPL 30/3157, and the experimental protocol was 
approved by the University of Bristol Animal Welfare and Ethical Review Body.   
 
2.2 Recruitment criteria 
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 4 
Advertisements to recruit participants for the study were posted on social media (Facebook, 
Twitter), within the local University of Bristol intranet, and within local veterinary practices. 
For the osteoarthritis (OA) group suitable dogs were 12 kg bodyweight and over, of any age, 
body condition and sex exhibiting suspected painful uni- or bilateral coxofemoral or stifle 
degenerative joint disease (DJD) as evidenced by lameness/stiffness/difficulty rising or 
ascending steps. Dogs with primarily forelimb lameness were excluded. During the study 
recruitment phase a large proportion of dogs screened were already receiving daily treatment 
with non-steroidal anti-inflammatory drugs (NSAIDs) for musculoskeletal pain and the 
decision was made to recruit these animals and permit them to continue daily NSAID 
treatment, but to designate them as a separate group (OANSAID) for analysis within the 
study. This decision was based on the fact that pain and disability were still present in these 
individuals despite treatment with the NSAID.  
 
The inclusion criteria for the control group were based on the demographics of a cohort of 
OA dogs recruited to a separate study at the University of Bristol [16], who recorded a mean 
(SD) age of 9.5 ± 3 years and weight of 27.5 ± 11.6 kg. For the present study dogs were 
recruited to the control group that were 6 years old or greater and 12 kg bodyweight and over, 
exhibiting no evidence of lameness or stiffness and with no other painful condition (e.g. otitis 
externa) and no previous diagnosis of OA. Figure 1 illustrates the outcomes for all dogs that 
attended screening and the subsequent numbers that were used at each stage of the study.  
 
2.3 Study protocol  
Owners of eligible dogs were asked to attend a screening appointment, at which the purpose 
and procedures of the study were explained verbally and in writing, and signed consent to 
participate was obtained prior to any study procedures being performed. Dogs underwent 
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 5 
physical and musculoskeletal examination by a veterinarian (JRH). Body condition score (1, 
emaciated – 9, morbidly obese [24]) was assessed by manual palpation. Any dogs with 
identifiable co-morbidities which would have an increased risks associated with general 
anaesthesia, or dogs with neurological dysfunction evidenced by weak or absent conscious 
proprioception, were excluded from the study. Microchip details were confirmed as a means 
of permanently identifying participating dogs to comply with the terms of the A(SP)A. 
Owners were asked to complete the ACVS Canine Orthopaedic Index [9], the Helsinki 
Chronic Pain Index (HCPI) [17], the Liverpool Osteoarthritis in Dogs (LOAD) questionnaire, 
the Canine Brief Pain Inventory (CBPI) [10], and the Sleep and Night time Restlessness 
Evaluation (SNORE) [22]. Jugular blood samples were obtained and submitted for routine 
biochemistry and haematology prior to scheduling general anaesthesia.  
  
2.4 Musculoskeletal examination (appendix 1) 
Scores for lameness (0-10) and mobility (0-3) were assigned by a veterinarian (JRH), 
according to the criteria shown in appendix 1.  
Examination of each joint was performed and individual appendicular joints were scored 
from 0 (not affected) to 3 (severely affected) for the criteria “range of motion”, “pain on 
extension or flexion”, “crepitus”, “effusion” and “thickening”. The sum of the joint disease 
scores produced an overall OA score between 0 and 192, while the sum of the pain scores for 
each joint produced an overall joint pain score between 0 and 48.  
 
2.5 General anaesthesia 
Seven days after the initial screening appointment dogs were admitted to the Wellcome 
Comparative Anaesthesia Research Laboratory, Langford, Bristol in order to undergo 
radiography and NWR testing under general anaesthesia.  
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On admission, confirmation that dogs had had food withheld for 8 hours was sought from 
owners and a veterinary examination was repeated.  
Acepromazine (ACP 2mg/ml solution, Elanco Animal Health, Basingstoke, UK) was 
administered intramuscularly (0.03mg kg-1) and dogs were left undisturbed for 30 minutes, 
following which a cephalic venous catheter was placed. Insufficient sedation to permit 
intravenous catheterisation warranted exclusion from the study.  
Alfaxalone (Alfaxan, Jurox (UK) Ltd, Crawley, UK) (1-2 mg kg-1) was administered 
intravenously over a period of 60 seconds until orotracheal intubation was possible. Oxygen 
was delivered via a circle breathing system and anaesthesia maintained with a constant rate 
infusion of alfaxalone (0.1 mg kg-1 min-1) during radiography, reducing to 0.09 mg kg-1 min-1 
for NWR testing. Body temperature was monitored every 30 minutes and supported with 
insulated electric blankets. Following NWR testing alfaxalone infusion was discontinued and 
the dogs constantly monitored until they were discharged to the owner once able to walk and 
having eaten. All dogs not ordinarily receiving NSAIDs were treated with meloxicam 
(Metacam 5mg/ml solution, Boehringer Ingelheim, Bracknell, UK) (0.2 mg kg-1) to treat any 
pain caused by positioning for radiography or NWR recording.  
 
2.6 Radiography 
Lateral and cranial-caudal views of the elbows and stifles; lateral views of the lumbosacral 
junction; and ventrodorsal views of the pelvis and coxofemoral joints were obtained in the 
Bristol Veterinary School imaging suite. Each of these seven joints was assessed for severity 
of radiographic osteoarthritis by two investigators (ME, BDXL) who were unaware of the 
OA group classification of the dogs. The investigators assigned scores from 0 (no 
radiographic signs of osteoarthritis) to 10 (severe radiographic osteoarthritis) for each joint 
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and a thus a global score for each dog out of 70 was recorded. The investigators performing 
NWR testing remained unaware of the results of the radiographs. 
 
2.7 Nociceptive Withdrawal Reflex testing 
Dogs were positioned in left lateral recumbency with the right pelvic limb resting on a 
sandbag, perpendicular to the table top. Paired stimulating electrodes (disposable subdermal 
needle electrode 12 x 0.40 mm, Natus Neurology Inc. Middleton, WI, USA)  
were placed 10mm apart subdermally into the plantar aspect of digit 3 of the right hindlimb; 
paired recording electrodes were placed 20mm apart into the body of the right cranial tibial 
muscle, and a ground electrode placed subcutaneously dorsal to the dorsal spinous process of 
L6. As previously described [23] the recorded signal was processed via a differential 
amplifier (DAM50, World Precision Instruments, Herts, UK) which applied a bandpass filter 
from 10 - 1kHz and gain of 1000, and was subsequently captured in Labchart 8 software (AD 
instruments, Oxford, UK) following conversion by an analogue to digital converter with a 
sampling frequency of 1kHz (Powerlab 4/35, AD instruments, Oxford, UK).  
 
2.8 EMG threshold 
Electrical stimuli were delivered via the toe electrodes using a constant current stimulator 
from an isolated 100 V source (Stimulus isolator FE180, AD instruments, Oxford, UK).  
The threshold current at which a single 1ms square wave stimulating pulse would evoke a 
visually discernable cranial tibial (CT) EMG response (a response greater than the baseline 
amplitude) was identified by increasing current stepwise from 0 to a maximum of 10mA in 
0.5mA increments. Following a response, the current was decreased by 0.1mA increments 
until the response was no longer elicited. This up and down adjustment was continued until 3 
stable readings for threshold were obtained at 60 second intervals.    
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2.9 Stimulus Response Curve 
One stimulus event comprised five 1ms stimuli (Train-of-5, To5 [23]), which were delivered 
at a frequency of 100 Hz. An EMG stimulus response determination was performed by 
triggering To5 events at 60-second intervals using currents of 0.1 (baseline), 1, 2, 3, 4, 5, 6, 7, 
8, 9 and 10 mA. The complete series of stimulating currents were applied in the same 
ascending order on a second occasion following a five-minute interval.   
 
2.10 Temporal Summation 
A stimulus sequence of 8x 1ms 10mA stimuli delivered at a rate of 1Hz was repeated 3 times 
at five-minute intervals.  
 
2.11 EMG analysis  
Post recording, a 10Hz high pass digital filter was applied to the EMG traces, to further 
decrease movement artefact. The primary outcome measure for the study was the integral of 
the rectified EMG response which was extracted for each stimulus within each pre-defined 
time window. The EMG response was designated as early (representing an A-fibre response 
0-100ms) or late (C-fibre; 100-500ms) latency, time locked to the start of the stimulus train 
[23]. Although the late response may also contain components of supraspinal origin, this 
differentiation was based on previous work in dogs [8] where conduction velocity of the 
different nerve fiber types and the length of the afferent distance were used to calculate 
latency ranges for the different (A and C fiber) responses. Baseline activity in the absence of 
any electrically-evoked response (the 0.1mA stimulus for the stimulus response experiments 
and from within a 2s period prior to application of the first of the eight stimuli for temporal 
summation experiments) was subtracted from each measurement.  
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2.12 Statistical methods 
Recordings of NWR data were visually examined by two investigators (JRH, JH) and where 
no identifiable response could be appreciated to a stimulation protocol the data for that 
protocol for the individual dog were excluded from the analysis. Sex distribution data were 
analysed using Chi squared tests. Comparisons of mean or median measures at single time 
points (e.g. body weight, lameness, owner completed metrology instruments) between the 
three groups were performed using one-way ANOVA or Kruskal-Wallis tests followed by 
Tukey (or Dunn’s) post-hoc testing if applicable. The hierarchical structure of the data 
comprising the stimulus response and temporal summation data was accounted for by 
employing multilevel modelling within the MLwiN statistics package [35]. In the case of the 
stimulus response data, no transformation of the outcome variable was necessary as the 
residuals from the analyses showed appropriate normality and homoscedasticity. It was 
necessary to apply natural log transformation to the temporal summation data to meet the 
assumptions of the statistical models. Data analysed using parametric tests are presented as 
mean (95% confidence interval (CI)) and the results of non-parametric testing are presented 
as median (25-75% interquartile range). The final multilevel, general linear models took the 
form of equations which described the effect of the statistically significant predictor variables 
on the outcome measures. The parameter estimates from the analyses are presented below 
and the models are represented as graphs. 
 
2.13 Power calculation 
A power calculation for the overarching project, based on preliminary data using von Frey 
mechanical threshold data, indicated a total of 68 dogs, evenly divided between OA and 
control groups, would be required for a power of 90%, at an alpha of 0.05 to detect a 
difference between control and OA dogs. However, this calculation assumed uniformity 
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within the OA group, whereas we suspected that the OA group would be heterogenous, based 
on data from human OA patients and laboratory animal models of OA. In humans, up to 70% 
of OA patients have at least one somatosensory abnormality [41]. Based on this, we 
estimated that recruiting 100 OA dogs would give us an appropriate cohort of central 
sensitisation (CS) negative dogs (i.e. approximately the same number as control dogs), and a 
cohort of CS positive dogs that may be as large as 70.  
 
Part ii) DNIC investigation 
 
2.14 Animals  
Following completion of the NWR/TS protocol described above, some dogs underwent 
DNIC investigations during the same anaesthetic period (see figure 1).  
 
2.15 DNIC protocol 
Five minutes after the final TS experiment, the DNIC protocol began by recording EMG 
responses in the CT muscle to test stimuli delivered at twice the individually determined 
threshold current (2xThr) at a rate of 1Hz for 100 seconds. This occasion was denoted ‘pre-
DNIC’. An identical test stimulation protocol (2xThr, 1Hz, 100 seconds) was repeated on 
three more occasions at five minute intervals; however, during occasions two (‘DNIC 1’) and 
three (‘DNIC 2’), the effect on CT responses of an additional mechanical conditioning 
stimulus, comprising a bulldog clip applied for 20 sec to the 3rd digit of the contralateral 
forelimb, was assessed (figure 2). The fourth and final occasion (‘post DNIC’) was a repeat 
of the pre-DNIC stimulating protocol, without the addition of a conditioning stimulus.  
Measurement of the force delivered by the bulldog clip at a jaw separation of 11 mm (mean 
jaw opening measured during the application to the digit) was achieved using a Loadcell 50N 
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gauge (Mecmesin, Slinfold, West Sussex, UK). The force recorded by the gauge at 11mm 
separation was 33.4 N, but this was also found to be consistent over the range of jaw opening 
from 2-12mm. Examination of the site of application following the DNIC protocol, and 7 
days later, demonstrated no evidence of immediate or delayed ongoing pain or tissue damage. 
 
2.16 Statistical methods 
Sex distribution data were assessed using Fisher’s exact test. Comparisons of weight and 
owner completed metrology instrument scores between the two groups were performed using 
Student’s t-test or Mann-Whitney U test.  The hierarchical structure of the DNIC testing data 
was accounted for within the statistical analysis by employing general linear modelling 
within a multilevel modelling framework using the MLwiN statistics package [42]. Predictor 
variables were retained within the model based upon a Wald test at α ≤ 0.05. It was necessary 
to apply a natural log transformation to the EMG magnitude data, to meet the assumptions of 
the tests with regards to normality and homoscedasticity of residuals. The pre-DNIC occasion 
was denoted as the reference occasion for comparisons within the model. Data subject to 
parametric tests are presented as mean (95% confidence interval (CI)) and results subject to 
non-parametric testing are presented as median (25-75% interquartile range). 
 
2.17 Power calculation 
A power calculation was performed for the overarching project; however, the DNIC 
investigation was performed in order to develop an effective but non-tissue damaging model 
for evaluating DNIC in dogs, and to provide pilot data for ongoing investigations, hence a 
power calculation was not performed specifically with regard to the primary outcome 
measure (magnitude of EMG response) reported here.  
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3. Results 
Part i) NWR/TS investigation 
3.1 Demographics 
Data were analysed from 27 control, 46 OA, and 29 OANSAID dogs. Breed and sex 
distribution are shown in table 1. There was no significant difference in sex distribution, and 
breed distribution appeared to be visually well matched between groups. Weight and body 
condition scores were not different between groups (table 1). Dogs in the control group were 
younger than dogs in both the OA and OANSAID groups (table 1). The duration of NSAID 
treatment in the OANSAID group was variable between individuals, but animals had been 
receiving daily NSAIDs for at least 3 months prior to recruitment to the study.  
 
 
3.2 Veterinary assessment 
Degree of lameness, mobility score, total osteoarthritis score, and total joint pain score were 
all significantly higher in OA and OANSAID groups compared with controls (table 2); 
however, there were no differences between OA and OANSAID groups with regard to these 
measures.  
 
3.3 Owner completed clinical metrology instruments (CMI) 
Questionnaire data were analysed by subsection if the questionnaire was constructed in a 
section format. Owner attributed scores for all of the questionnaire subsections were 
significantly higher (more dysfunction/pain) in OA and OANSAID animals compared with 
controls. Additionally, the CBPI pain and ACVS function subsections were significantly 
higher in OANSAID compared with OA animals (table 2), indicating that dogs receiving 
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NSAID therapy experienced greater pain and greater dysfunction (e.g. reduced mobility) than 
dogs with OA that were not receiving NSAID treatment.  
 
3.4 Radiographic scores 
Radiographic osteoarthritis severity was significantly higher in both OA and OANSAID 
animals compared with controls, but was not significantly different between OA and 
OANSAID animals (table 2).  
 
3.5 NWR recordings 
The early phase of the NWR could be reliably and repeatedly elicited in the cranial tibial 
muscle during the multiple trials at each stimulus intensity. Examples of raw traces obtained 
during NWR recording are provided (Figures 3 and 4). 
  
3.6 Electrical threshold 
The threshold current to elicit an EMG response was significantly lower in control (2.3 
(95%CI 1.8 – 2.9mA)) compared with OA dogs (3.8 (95%CI 3.0 – 4.6mA) (F2,93 = 3.859, p = 
0.02) but neither group was different from OANSAID (3.2 (95%CI 2.4 – 3.9mA) which had 
an intermediate value.    
 
3.7 Stimulus response (table 3) 
Only the early component of the response was analysed, as the late response was absent in 
the majority of recordings. The parameter estimates of those predictor variables significantly 
associated with the response are presented in table 3. The final model, containing only the 
significant terms, demonstrated that the magnitude of the measured response increased as a 
curvilinear function of the stimulating current (mA). There was a significant negative 
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interaction between bodyweight and stimulating current (weight.mA; p < 0.001); larger 
animals demonstrated a lesser increase in response magnitude with increasing current 
compared with smaller animals. There was a significant positive interaction between the 
OANSAID category and stimulating current (OANSAID.mA) compared with control (p < 
0.001) and OA category (p < 0.001) animals; OANSAID category animals demonstrated 
increased magnitude responses at a given stimulating current, compared with both control 
and OA category animals. These relationships are shown graphically in figure 5, at a fixed 
weight of 25 kg. 
 
3.8 Temporal summation early (A-fibre) response (table 4) 
The magnitude of A-fibre responses increased with increasing stimulus number from 1-8 
within each repetition of the protocol (temporal summation) (p < 0.001), but was reduced on 
the third (final) occasion of the temporal summation (train of 8) protocol, compared with the 
first (p = 0.013). Higher weight animals demonstrated reduced magnitude responses to 
stimulation (p = 0.001), and lesser increases in magnitude of response with increasing 
stimulus number (weight.stimulus number interaction) (p = 0.009). OA and OANSAID 
animals did not differ from control.   
 
3.9 Temporal summation late (C-fibre) response (table 4) 
The temporal summation protocol consistently elicited late responses. The magnitude of the 
late (C-fibre) response increased with increasing stimulus number from 1-8 within each 
repetition of the protocol (temporal summation) (p < 0.001) but was decreased on both the 
second and third occasion of repeating the protocol (train of 8) compared with the first trial. 
Higher weight animals demonstrated lesser increases in magnitude of response with 
increasing stimulus number (weight.stimulus number interaction; p < 0.001), and older 
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animals also demonstrated lesser increases in magnitude of response with increasing stimulus 
number (age.stimulus number interaction; p = 0.001). Both OA (OA.stimulus number 
interaction; p < 0.001) and OANSAID (OANSAID.stimulus number interaction; p = 0.005) 
category animals demonstrated larger increases in magnitude of response with increasing 
stimulus number compared with control animals (figure 6) but there were no differences 
between the OA and OANSAID groups. 
 
Part ii) DNIC investigation 
3.10 Demographics  
Data were analysed from 12 control and 11 OA dogs (none receiving NSAIDs). The sex 
distribution between the groups was not different, and the distribution of breeds appeared 
well matched on visual inspection (table 5). OA dogs were significantly older than control 
dogs (table 5). Groups were not different in terms of weight; however, body condition score 
was higher in OA (6, 5-7) compared with control dogs (5, 4.25-5.75, p = 0.047).  
 
3.11 Veterinary musculoskeletal and gait assessments 
Degree of lameness, mobility impairment, OA burden and joint pain burden were all 
increased in OA compared with control dogs (table 6).  
 
3.12 Owner completed clinical metrology instruments (CMI) 
The CBPI, HCPI, ACVS COI, and LOAD were all rated significantly higher by owners of 
OA compared with control dogs (table 6) but there was no significant difference in scores for 
the SNoRE questionnaire.  
 
3.13 Radiography 
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Significantly more radiographic signs of osteoarthritis were identified in dogs in the OA 
compared with control group, and significantly more of the seven joints assessed 
demonstrated radiographic signs of OA in OA compared with control dogs (table 6). 
 
3.14 NWR threshold 
The threshold current required to elicit a NWR was significantly higher in OA (3.8 (95% CI 
2.4-5.2 mA)) compared with control dogs (1.9 (95% CI 1.4-2.5 mA), p = 0.013) (table 6). 
 
3.15 DNIC efficacy 
 
The 2xThr stimulation did not elicit consistent late responses, therefore only the early (0-
100ms) latency response was analysed [19].  
 
The final, significant general linear model which described the magnitude of the early 
response took the form of an equation, the parameter estimates of which and p- values 
associated with the predictor variables within the model are presented in table 7.  The 
predictor variables and their relationship with the magnitude of the response are described 
below. Time and age were considered continuous scale variables. Each occasion of DNIC 
testing (pre, DNIC 1, DNIC 2, post) was considered a categorical variable, as was OA status 
(OA/control).  Figure 7 shows the effect of mechanical "conditioning" stimulation of the 
forepaw on electrically evoked "test" EMG reflexes in the cranial tibial muscle of the 
contralateral hindlimb. 
 
3.15.1 Stability of response magnitude within occasion 
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Time alone did not account for a significant variation in magnitude within a test occasion (p 
= 0.069). 
 
3.15.2 Stability of response magnitude between occasions 
Between different test occasions, response magnitude was decreased in DNIC 1 and 2, and in 
the post DNIC state, compared with the original pre DNIC occasion (p = 0.048, <0.001, and 
< 0.001 respectively), indicating a decreasing magnitude of response with repeated occasions 
of the stimulating protocol. 
 
3.15.3 Efficacy of DNIC stimulus 
There was a significant interaction between time and occasion for DNIC 1 and 2 (p <0.001), 
but not between time and occasion post DNIC (p = 0.50), demonstrating that the application 
of the conditioning stimulus was responsible for significantly decreasing the response 
magnitude during DNIC 1 and 2 compared to the pre-DNIC occasion. The interaction 
between square and cubic terms of time, and DNIC 1 and 2, were significant, indicating a 
curvilinear change of response with application of the conditioning stimulus.   
 
3.15.4 Effect of OA status 
OA status alone had no significant effect on response magnitude (p = 0.31); however, there 
was a significant interaction between OA status and occasion during the DNIC 2 (p = 0.003) 
and post DNIC (p = 0.02) testing, which predicted a higher magnitude of response (i.e. 
decreased inhibition of response) in OA dogs during these two occasions, compared with 
control dogs. Inclusion of the overall interaction between OA status and DNIC occasion as a 
predictor variable significantly improved the model (change in log likelihood = 7.82, df3; p = 
0.0499).  
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 18 
 
3.15.5 Effect of age 
The effect of age was tested within models but found to be not significant as either a main 
effect within the model, nor in interaction with other terms within the models.  
 
 
4. Discussion  
The present studies have shown that several characteristics of the CT NWR were altered in 
dogs with OA, therefore central neurophysiological changes may play a role in the pathology 
of OA-associated pain and disability in dogs. DNIC investigations suggest that these central 
changes may be related in part to less effective descending inhibition of nociceptive stimuli.  
 
In man the RIII (Aδ-fibre mediated) threshold is correlated with the pain threshold [36], and 
is decreased in painful osteoarthritis states [12]. We anticipated that dogs exhibiting central 
sensitisation would demonstrate a diminished threshold to elicit a NWR, however our results 
indicated that threshold current was higher in OA animals compared with controls. The 
underlying reason for this finding is difficult to explain. The early latency (0-100ms) 
response elicited by NWR stimulation in our testing paradigm comprises both Aβ- (RII 
equivalent in man) and Aδ- (RIII equivalent) transmission. The RII response in man is 
considered non-nociceptive and elicited by sub-pain threshold intensities of stimulation. 
Central sensitisation may be accompanied by hypoaesthesia to one or more sensory 
modalities in human subjects [18], therefore it is possible that the greater threshold identified 
in OA dogs relates to Aβ-mediated hypoaesthesia. Whilst it may have been desirable to 
further divide the responses by latency into Aβ- or Aδ- mediated, as reported by Bergadano et 
al (2006) [6], we undertook testing in a mixed population of dogs with a range of weights and 
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conformations, which would have added to the variability in response latency. Visual 
inspection of pilot data traces revealed that we could only consistently identify an early (A-
fibre) and late (C-fibre) response [19]. We could have considered measuring the afferent 
distance of the conduction pathway in individual animals and using this, together with an 
estimate of conduction velocity, to calculate more accurately the latency window of the NWR 
in each individual dog. However our inclusion criteria for the study limited the weight range 
of the dogs included in the study therefore this was not deemed necessary for the present 
investigation. 
 
The stimulus response curve demonstrated facilitation of the early response in OANSAID 
dogs, compared with both control and OA dogs. The amplitude of the RIII response has been 
shown to correlate with the magnitude of subjective pain in conscious human volunteers [13]; 
therefore the inference from our data is that OANSAID dogs may exhibit hyperalgesia, 
compared with dogs in both the OA and control groups. That the OA and OANSAID groups 
were not different based on veterinarian examination scores and radiographic OA scores was 
not unexpected – there are no validated veterinarian assessment systems of OA pain, and 
radiographic evidence of OA is known not to correlated to pain, just as in humans. Although 
OA and OANSAID groups were comparable with respect to the majority of the clinical 
metrology instrument (CMI) data, OANSAID were significantly more affected with respect 
to the CBPI pain and the ACVS description of function subscales, and had higher scores on 
all the other validated CMIs (LOAD, CBPI function). These data indicate the OANSAID 
group were more severely affected by OA pain, and suggest that treatment with commonly 
prescribed veterinary NSAIDs [20] may not prevent or reverse central sensitisation, despite 
the tentative conclusion from a recent study in humans with OA investigating etoricoxib [1]. 
The total duration of treatment with NSAIDs in the OANSAID group was not recorded in 
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individual dogs in this study and it is possible that differences in the duration of 
administration introduced variability into the data. However, all dogs in the OANSAID group 
had been receiving NSAIDs for at least 3 months prior to recruitment to the study which, 
from early data in humans [1] would be sufficient time for the NSAID to exhibit an anti-
hyperalgesic effect.  
 
Temporal summation data demonstrated no group differences for the early (A-fibre mediated) 
response, but facilitation of the late (mostly C-fibre) response in OA and OANSAID dogs, 
compared with controls. The absence of an effect on the early response data is likely due to a 
significant component being mediated by low threshold A beta fibres. The applied 10mA 
stimulus, designed as a suprathreshold stimulus, would cause the early response to saturate at 
this level of stimulation, and therefore differences between groups were minimised. In 
contrast the higher threshold C-fibre mediated late response displayed the expected 
increasing magnitude with repeated stimuli and, in alignment with our hypothesis, was 
augmented in both OA and OANSAID groups compared with the control group. This likely 
indicates that OA is associated with central sensitisation in dogs. It is also possible that the 
EMG findings for C fibre mediated responses are due to C fiber sensitisation rather than 
central sensitisation although it is difficult to make a distinction between these two effects in 
our data set. 
 
 
The data produced during the DNIC investigation demonstrate both that MCS elicits 
quantifiable DNIC in anaesthetised dogs, and that the efficacy of DNIC is compromised in 
dogs with OA, compared with a control group. A recent meta-analysis concluded that, despite 
methodological limitations, a number of chronic pain conditions in man, including 
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osteoarthritis, are associated with reduced efficacy of CPM [28]. Reduced net efficacy of 
nociceptive inhibition may arise through impaired descending anti-nociceptive modulation, 
or via descending facilitation of nociceptive signalling [3]. We did not probe each of these 
pathways independently in these clinical cases; however, the magnitude of measured EMG 
response in this study represents the net effect of balance between inhibitory and facilitatory 
mechanisms, therefore these data provide evidence that the balance of descending pathways 
becomes shifted toward pro-nociception in canine OA.  
 
The differences between OA and control groups were only evident on DNIC 2, and then 
persisted into the post DNIC period. Because previous data on DNIC in dogs using MCS 
were not available, numbers required to identify significant differences were unknown, 
however it is clear from our results that the interaction between group and occasion begins to 
approach significance during DNIC 1 (p = 0.07). Had larger sample sizes been employed we 
would have had greater power to detect differences between groups, and may have identified 
a significant difference during DNIC 1. The small sample size is a major limitation of the 
DNIC investigation and reflected difficulties in establishing the methodology to elicit DNIC 
in dogs. Only five minutes was allowed to elapse between the temporal summation protocol 
and the start of the DNIC investigation. This time period was kept deliberately short to avoid 
prolonging the anaesthesia time for the dogs as far as possible. It is possible that delivery of a 
supramaximal stimulus during the temporal summation protocol sensitised the nociceptive 
system so that the nociceptive pathways were not in a naïve state at the start of the DNIC 
experiment and this may have affected our DNIC results. The optimal time delay between 
temporal summation and measurement of DNIC is currently unknown. 
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NWRs are segmental spinal reflexes, subject to supraspinal modulation [11]. Alfaxalone 
anaesthesia enabled NWR recording in client owned dogs. Whilst alfaxalone increases NWR 
threshold and decreases magnitude of response to electrical stimulation [19] there is no 
reason to expect a differential effect of the anaesthetic on control versus OA or OANSAID 
animals, as alfaxalone is devoid of analgesic activity [40].  
With regards to assessment of DNIC, many sedatives and analgesics will interact with 
descending pro- and anti-nociceptive pathways [27,37] and could alter the measured 
responses. Acepromazine has been shown not to modulate NWR [7] and, given it is 
considered to have no anti-nociceptive properties [4], would not be expected to interact with 
descending modulatory mechanisms. Alfaxalone is a gamma amino butyric acid (GABA) 
agonist, and DNIC is reportedly unaffected by GABA agonists [23], therefore we consider 
that the form of anaesthesia employed was appropriate to our investigation.  
 
Although we have identified group level differences in DNIC efficacy, the aim is ultimately 
to identify individuals in which decreased DNIC efficacy contributes to the pain phenotype, 
and address this mechanism therapeutically [3]. Determining a normal ‘range’ of DNIC 
responses in dogs will require study of additional numbers of dogs of a wider demographic, 
particularly in view of the inconsistently reported gender [33] and age [25] differences 
associated with CPM in man.  
 
In conclusion, we have demonstrated a number of neurophysiological changes indicative of 
central sensitisation processes in dogs affected by spontaneous osteoarthritis, consistent with 
findings in man. However, measurement of electrical thresholds appeared not to be a suitable 
parameter for central sensitisation using the current methods. The mechanisms involved may 
encompass both upregulation of nociceptive afferent pathways [26], in addition to alterations 
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in the balance of descending modulatory mechanisms as shown here. Increasingly it appears 
that the pathophysiological mechanisms of human OA [21] are shared by the spontaneous 
disease in dogs, further validating canine spontaneous OA as a model for the human disease 
[32,39] and supporting the use of dogs for mechanistic clinical trials to advance therapeutic 
development in humans. 
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7. Figure Legends 
 
Figure 1 Illustration of the number of animals recruited to each OA category, and attrition 
through different stages of the study. 
 
Figure 2 During anaesthesia, a bulldog clip conditioning stimulus was applied for 20 seconds 
to the third digit of the left cranial limb, whilst electrical test stimuli were delivered to the 
right pelvic limb.  
Figure 3: An example of temporal summation in the cranial tibial muscle (recorded from dog 
71). The top channel is a stimulus marker channel, with a train of 8 1ms 10 mA stimuli 
delivered at a frequency of 1 Hz. The lower channel shows the early and late responses in the 
cranial tibial muscle. The time base is 0.2s/division. 
 
Figure 4: An example of the electrical stimulus response curve recorded from the cranial 
tibial muscle in dog 98. The top channel is the stimulus marker channel, with each single line 
representing five 1 ms stimuli delivered at a frequency of 100 Hz. Eleven stimuli were 
delivered with a 60 second interval between them starting at 0.1 mA (baseline), 1 mA and 
increasing in 1 mA increments through to 10 mA. The middle channel shows the early 
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responses in the cranial tibial muscle and the lower channel shows the rectified EMG 
response in the cranial tibial muscle. The time base is 0.2s/division 
 
Figure 5 Illustration of the mean curves predicted by the general linear model for stimulus 
response of dogs within differing OA categories, assuming a weight of 25kg. Each data point 
for the control animals is based on 27 dogs, for the OA group it is based on 46 dogs and for 
the OANSAID group it is based on 29 dogs. For each animal the mean response to the two 
repetitions of the stimulus response curve was averaged prior to analysis. The Y axis 
represents the natural logarithm of the magnitude of the EMG response and the X axis shows 
the magnitude of the stimulating current. 
 
Figure 6 Illustration of the mean curves predicted by the general linear model for the first 
occasion temporal summation late response for dogs within differing OA categories, 
assuming a weight of 25kg and age of 9 years. The Y axis represents the natural logarithm of 
the magnitude of the EMG response and the X axis shows stimulus number. 
 
Figure 7 Effect of mechanical "conditioning" stimulation of the forepaw on electrically evoked 
"test" EMG reflexes in the cranial tibial muscle of the contralateral hindlimb. Clip was applied 
at time 0 for 20 secs. In the control group EMG responses to the test stimulus were reduced 
(greater % reduction in EMG) during clip application, indicating antinociception and a DNIC 
effect. When all time points were considered DNIC in the OA group (n = 11) was significantly 
less compared to control animals (n = 12) (P=0.016). Responses are medians, errors are  75th 
percentiles. 
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Summary:  
Spinal nociceptive transmission, and descending modulation, were studied in dogs with 
spontaneous osteoarthritis. Osteoarthritis was associated with augmented reflexes and 
reduced descending inhibition, suggesting central sensitisation.  
 
Summary
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Breed Control (n = 27) OA (n = 46) OANSAID (n = 29) p 
Border collie 7  10 5 - 
Labrador 5  8 11 - 
Retriever 3 3 1 - 
Lurcher 3 2 0 - 
Spaniel 1 5 3 - 
Other 8 18 9 - 
 
Sex     
M 3 3 3 0.61 
Mn 7 18 14 0.61 
F 1 3 2 0.61 
Fn 16 22 10 0.61 
 
Weight (kg) 22.8 (95%CI 
20.5-25.0) 
26.8 (95%CI 
23.6-29.9) 
28.7 (95%CI 24.8-
32.6) 
0.0563 
Body condition 
score (1-9) 
5 (4-6) 5 (5-6) 5 (4-6) 0.19 
Age (years) 7.8 (95%CI  
7.3-8.4)a 
9.8 (95%CI  
9.2-10.3)b 
9.6 (95%CI  
8.5-10.6)b 
< 0.001*** 
Table 1 Demographics M Male, Mn Male neuter, F Female, Fn Female neuter. Superscript letters indicate groupings within 
the data, shared superscripts indicate no significant difference between groups on post-hoc testing, differing superscripts 
indicate a difference with a p– value of less than 0.05 on post-hoc testing. * p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001 
 
Table 1
 Control OA OANSAID p 
Lameness (0-10) 0 (0-0)a 3 (1-3)b 3 (2-3)b,c <0.001*** 
Mobility (0-3) 0 (0-0)a 1 (1-1)b 1 (1-1)b,c <0.001*** 
OA score (0-192) 0 (0-2)a 10 (7-16)b 14 (9-19)b,c <0.001*** 
Joint pain score 
(0-48) 
0 (0-0)a 4 (2-4)b 4 (3-5)b,c <0.001*** 
CBPI pain (0-10) 0 (0-0.0625)a 1.75 (0-3.5)b 3.375 (1.813-
4.688)c 
<0.001*** 
CBPI function 
(0-10) 
0 (0-0.833)a 1.167 (0.1667-
4.50)b 
2.833 (1.50-
5.042)b,c 
<0.001*** 
HCPI (0-44) 3 (0-8.25)a 14 (8-22)b 20.5 (15.25-
21.75)b,c 
<0.001*** 
ACVS stiffness 
(0-16) 
0 (0-0.25)a 5 (2-8)b 8 (5-9)b,c <0.001*** 
ACVS function 
(0-16) 
0 (0-0.25)a 5 (1-8)b 8 (6-12)c <0.001*** 
ACVS gait (0-
20) 
0.5 (0-2.25)a 7 (2-11)b 9 (7-11.75)b,c <0.001*** 
ACVS QoL (0-
12) 
0 (0-1)a 3 (1-5)b 4.5 (2.6)b,c <0.001*** 
LOAD (0-52) 2 (0-5)a 14 (9-23)b 18.5 (12-23)b,c <0.001*** 
Radiographic OA 
score (0-70) 
3 (1-10)a 14 (8.25-
24.75)b 
20 (8-26)b,c <0.001*** 
Table 2 Musculoskeletal examination, owner completed metrology instrument and radiographic severity data. Superscript 
letters indicate groupings within the data, shared superscripts indicate no significant difference between groups on post-hoc 
Table 2
testing, differing superscripts indicate a difference with a p– value of less than 0.05 on post-hoc testing. * p ≤ 0.05; ** p ≤ 
0.01; *** p ≤ 0.001 
 
 Response 
magnitude 
(mV.s) 
S.E. Conf Int 
2.5% 
Conf Int 
97.5% 
p-value 
      
intercept -0.001230 0.003234 -0.007569 0.005109 0.704 
weight 0.000018 0.000113 -0.000204 0.000240 0.873 
OA 0.000753 0.002481 -0.004110 0.005615 0.762 
OANSAID 0.000353 0.002782 -0.005100 0.005806 0.899 
mA 0.004864 0.000540 0.003807 0.005922 <0.001*** 
mA2 -0.000170 0.000052 -0.000271 -0.000069 0.001** 
weight.mA -0.000094 0.000019 -0.000132 -0.000056 <0.001*** 
weight.mA2 0.000004 0.000002 0.000001 0.000008 0.026* 
OA.mA -0.000092 0.000119 -0.000325 0.000141 0.440 
OANSAID.mA 0.000759 0.000134 0.000497 0.001021 <0.001*** 
Table 3 Effect size estimates and p- values for the general linear model which was fitted to the stimulus response (early) 
data. * p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001 
 
Table 3
 temporal 
summation 
early 
response 
(lnmV.s) 
S.E. Conf Int 
2.5% 
Conf Int 
97.5% 
p-value Temporal 
summation 
late 
response 
(lnmV.s) 
S.E. Conf Int 
2.5% 
Conf Int 
97.5% 
p-value 
           
intercept -4.900 0.341 -5.569 -4.231 <0.001*** -7.142 0.700 -8.513 -5.771 <0.001* 
weight -0.040 0.012 -0.064 -0.017 0.001** 0.017 0.015 -0.012 0.046 0.246 
OA      -0.722 0.348 -1.404 -0.040 0.038* 
OANSAID      -0.254 0.362 -0.964 0.456 0.483 
Occasion 2 -0.022 0.019 -0.059 0.016 0.265 -0.058 0.026 -0.109 -0.007 0.026* 
Occasion 3 -0.048 0.019 -0.086 -0.010 0.013* -0.120 0.026 -0.171 -0.069 <0.001*** 
Stimulus number 1.084 0.145 0.800 1.369 <0.001*** 2.401 0.373 1.670 3.132 <0.001*** 
Stimulus number2 -0.243 0.036 -0.314 -0.171 <0.001*** -0.474 0.094 -0.658 -0.291 <0.001*** 
Stimulus number3 0.016 0.003 0.011 0.021 <0.001*** 0.030 0.007 0.016 0.043 <0.001*** 
weight.Stimulus number -0.014 0.005 -0.024 -0.003 0.009** -0.037 0.008 -0.053 -0.022 <0.001*** 
Table 4
weight.Stimulus 
number2 
0.004 0.001 0.001 0.006 0.006** 0.008 0.002 0.004 0.012 <0.001*** 
weight.Stimulus 
number3 
0.000 0.000 0.000 0.000 0.009** -0.001 0.000 -0.001 0.000 <0.001*** 
OA.Stimulus number - - - 0.805 0.186 0.442 1.169 <0.001*** 
OANSAID.Stimulus number - - - 0.540 0.193 0.161 0.919 0.005** 
OA.Stimulus number2 - - - -0.160 0.047 -0.251 -0.069 0.001** 
OANSAID.Stimulus number2 - - - -0.100 0.048 -0.195 -0.005 0.039* 
OA.Stimulus number^3 - - - 0.010 0.003 0.004 0.017 0.003** 
OANSAID.Stimulus number^3 - - - 0.006 0.004 -0.001 0.013 0.079 
age - - - 0.088 0.067 -0.043 0.218 0.187 
age.Stimulus number - - - -0.121 0.036 -0.190 -0.051 0.001** 
age.Stimulus number2 - - - 0.024 0.009 0.007 0.042 0.006** 
age.Stimulus number3 - - - -0.002 0.001 -0.003 0.000 0.016* 
Table 4 Effect size estimates and p- values for the general linear model which was fitted to the temporal summation data. * p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001 
 
Breed Control (n=12) OA (n=11) p 
Labrador 6 3 - 
Collie 2 1 - 
Retriever 2 2 - 
Lurcher 2 1 - 
German Shepherd 0 1 - 
Rottweiler 0 2 - 
Spaniel 0 1 - 
    
Sex    
Male neuter 6 5 1.0 
Female neuter 6 6 1.0 
    
Weight 23.8 (95%CI 21.6-
26.1) 
31.3 (95% CI 23.2-
39.4) 
0.053 
Age 7.5 (95%CI 6.9-8.2) 9.8 (95%CI 8.5-11.1) 0.002** 
Body condition score 
(0-9) 
5 (4.25-5.75) 6 (5-7) 0.047* 
Table 5 Demographic data. * p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001 
 
Table 5
 Control OA p 
Lameness (0-10) 0 (0-0) 3 (3-3) <0.001*** 
Mobility (0-3) 0 (0-0) 1 (1-2) <0.001*** 
OA score (0-192) 0 (0-2) 9 (6-12) <0.001*** 
Joint pain score (0-48) 0 (0-0) 4 (2-5) <0.001*** 
CBPI pain (0-10) 0 (0-0) 1.125 (0-2.69) 0.0085** 
CBPI function (0-10) 0 (0-0) 2.375 (0-6.938) 0.0022** 
HCPI (0-44) 1 (0-1.75) 15.5 (3.5-20.5) 0.0026** 
ACVS stiffness (0-16) 0 (0-0) 5.5 (0-7) 0.0029** 
ACVS function (0-16) 0 (0-0) 4 (0-8.75) 0.0076** 
ACVS gait (0-20) 0 (0-0) 5 (2.25-11.5) 0.0022** 
ACVS QoL (0-12) 0 (0-0.75) 3 (0-6.25) 0.0076** 
LOAD (0-52) 2.5 (0-3) 15.5 (5-25) 0.0042** 
SNoRE 13.5 (10.5-18.5) 15.5 (14-25.25) 0.21  
Radiographic OA score 
(0-70) 
2 (0.25-3) 20 (16-28) <0.001*** 
Number of joints 
radiographically affected 
1 (0.25-2) 5 (2-6) <0.001*** 
NWR threshold 1.9 (95%CI 1.4-2.5) 3.8 (95%CI 2.4-5.2) 0.013* 
Table 6 Musculoskeletal examination, owner completed metrology instrument, radiographic scoring and nociceptive 
withdrawal reflex (NWR) data in dogs undergoing the DNIC protocol. * p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001 
 
Table 6
 Predictor variable Parameter estimate S.E. Conf Int 2.5% Conf Int 97.5% p-value 
Fixed Effects     
cons -5.420132 0.265083 -5.939685 -4.90058 <0.001*** 
DNIC1 -0.158861 0.095373 -0.345789 0.028067 0.048* 
DNIC2 -0.508912 0.095373 -0.695839 -0.321984 <0.001*** 
Post DNIC -0.433574 0.100943 -0.631419 -0.235729 <0.001*** 
Time -0.009741 0.006579 -0.022635 0.003153 0.069 
Time2 -0.000054 0.000418 -0.000873 0.000764 0.448 
Time3 0.000005 0.000007 -0.00001 0.000019 0.265 
OA -0.183357 0.381486 -0.931054 0.564341 0.315 
OA.DNIC1 0.181664 0.127397 -0.068029 0.431357 0.077 
OA.DNIC2 0.349945 0.127397 0.100251 0.599638 0.003** 
OA.postDNIC 0.271047 0.131377 0.013553 0.528541 0.020** 
Time.DNIC1 -0.055631 0.009303 -0.073866 -0.037397 <0.001*** 
Time2.DNIC1 0.003449 0.000591 0.002291 0.004607 <0.001*** 
Time3.DNIC1 -0.000052 0.00001 -0.000072 -0.000032 <0.001*** 
Time.DNIC2 -0.05043 0.009303 -0.068664 -0.032195 <0.001*** 
Time2.DNIC2 0.00353 0.000591 0.002372 0.004688 <0.001*** 
Time3.DNIC2 -0.000057 0.00001 -0.000077 -0.000037 <0.001*** 
Time.postDNIC 0.000054 0.009522 -0.01861 0.018717 0.497 
Time2.postDNIC 0.000264 0.000605 -0.000922 0.001449 0.331 
Time3.postDNIC -0.000006 0.00001 -0.000026 0.000015 0.299 
Table 7 Parameter estimates, se, 95% CIs  and p- values for the general linear model fitted to the stimulus response (early) 
data (ln(mV.s)). * p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001 
Table 7
Appendix 1, Criteria for scoring during musculoskeletal examination 
 
 
 
1. Lameness during locomotion (0-10) 
 
Lameness score (adapted from Vasseur and Slatter (1993) In. Text Book of Small Animal Surgery, 2nd Edition) 
0: Sound 
1: Occasionally shifts weight 
2: Mild Lameness at slow trot, none while walking 
3: Mild lameness while walking 
4: Obvious lameness when walking, but places foot when standing 
5-8: Increasing degrees of severity between 4 and 9 
9: Places toe when standing, carries limb when trotting 
10: Unable to put foot on ground 
 
 
2. Overall mobility impairment score (0-3) 
 
Score Descriptor 
0 Moves fluidly, easily, symmetrically. No 
hesitation. 
1 Mild stiffness at walk 
2 Moderate shuffling/stiff gait at walk. Moderate 
hesitation to initiate movement 
3 Pronounced shuffling/stiff gait at walk. Marked 
hesitation to initiate movement. Possibly 
arched back or disuse of limb compared to 
contralateral 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Materials: Appendix 1 Click here to download Supplementary Materials: figures,
tables Appendix 1.docx
3. Physical examination 
 Joint Evaluation: 
R Forelimb Range of 
Motion (0-3) 
Pain on E 
or F (0-3)  
Crepitus 
(0-3) 
Effusion 
(0-3) 
Thickening 
(0-3) 
Total  
Manus 
  
 
    
Carpus 
 
 
     
Elbow 
  
 
    
Shoulder 
 
 
     
Total        
 
L Forelimb Range of 
Motion (0-3) 
Pain on E 
or F (0-3)  
Crepitus 
(0-3) 
Effusion 
(0-3) 
Thickening 
(0-3) 
Total 
 
Manus  
 
 
 
    
Carpus  
 
 
 
    
Elbow  
 
 
 
    
Shoulder  
 
     
Total        
 
R Hindlimb Range of 
Motion (0-3) 
Pain on E or 
F (0-3)  
Crepitus 
(0-3) 
Effusion 
(0-3) 
Thickening 
(0-3) 
Total 
Manus 
  
 
    
Tarsus 
 
 
 
 
    
Stifle 
 
 
 
 
    
Hip 
 
 
     
Total       
 
L Hindlimb Range of 
Motion (0-3) 
Pain on E or 
F (0-3)  
Crepitus 
(0-3) 
Effusion 
(0-3) 
Thickening 
(0-3) 
Total 
Manus 
  
 
    
Tarsus 
 
 
 
 
    
Stifle 
 
 
 
 
    
Hip 
 
 
     
Total       
 
Key: 
Range of Motion  
0: normal; 1: mildly reduced, 2: moderately reduced; 3: severely reduced 
 
Pain scale based on extension or flexion 
0: no resentment; 1: mild withdrawal, mildly resist; 2: moderate withdrawal body tenses, may orient to site, may vocalize; 
3: orients to site, forcible withdrawal from manipulation, may vocalize or bite; tries to escape/prevent manipulation, bite, 
marked guarding of area 
 
Crepitus: 
0: none, no crunching; 1: mild, only feel crunching sometimes 2: moderate, crunching felt always, may be painful; 
3: severe, can feel and hear crunching, may be painful 
 
Effusion: 
0: none, no fluid pocket felt; 1: mild, small fluid pocket felt only on palpation; 2: moderate, prominent on palpation; 3: 
severe, may see visible fluid pocket 
 
Thickening:  
0: none, can feel all anatomic structures easily; 1: mild, less defined anatomic structures; 2: moderate, can slightly define 
anatomic structures; 3: severe, can no longer feel anatomic structures  
 
  
Copyright Transfer Agreement
Click here to access/download
Copyright Transfer Agreement
PAIN_eCopyright_Transfer_Form.pdf
  
Copyright Transfer Agreement
Click here to access/download
Copyright Transfer Agreement
H jenkins copyright.pdf
  
Copyright Transfer Agreement
Click here to access/download
Copyright Transfer Agreement
MGoff_PAIN_eCopyright_Transfer_Form.pdf
  
Copyright Transfer Agreement
Click here to access/download
Copyright Transfer Agreement
PAIN_Copyright_Transfer_Form - mm.pdf
  
Copyright Transfer Agreement
Click here to access/download
Copyright Transfer Agreement
PAIN_Copyright_Transfer_Form_Harris.pdf
  
Copyright Transfer Agreement
Click here to access/download
Copyright Transfer Agreement
PAIN_Copyright_Transfer_Form_Helen Whay.pdf
  
Copyright Transfer Agreement
Click here to access/download
Copyright Transfer Agreement
PAIN_Copyright_Transfer_Form-Lascelles.pdf
  
Copyright Transfer Agreement
Click here to access/download
Copyright Transfer Agreement
PAIN_Copyright_Transfer_FormMURRELL.pdf
  
Copyright Transfer Agreement
Click here to access/download
Copyright Transfer Agreement
PAIN_eCopyright_Transfer_FormME.pdf
  
Copyright Transfer Agreement
Click here to access/download
Copyright Transfer Agreement
TGK PAIN_eCopyright_Transfer_Form.pdf
Please wait... 
  
If this message is not eventually replaced by the proper contents of the document, your PDF 
viewer may not be able to display this type of document. 
  
You can upgrade to the latest version of Adobe Reader for Windows®, Mac, or Linux® by 
visiting  http://www.adobe.com/go/reader_download. 
  
For more assistance with Adobe Reader visit  http://www.adobe.com/go/acrreader. 
  
Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark 
of Apple Inc., registered in the United States and other countries. Linux is the registered trademark of Linus Torvalds in the U.S. and other 
countries.
ICMJE Conflict of Interest Form
Please wait... 
  
If this message is not eventually replaced by the proper contents of the document, your PDF 
viewer may not be able to display this type of document. 
  
You can upgrade to the latest version of Adobe Reader for Windows®, Mac, or Linux® by 
visiting  http://www.adobe.com/go/reader_download. 
  
For more assistance with Adobe Reader visit  http://www.adobe.com/go/acrreader. 
  
Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark 
of Apple Inc., registered in the United States and other countries. Linux is the registered trademark of Linus Torvalds in the U.S. and other 
countries.
ICMJE Conflict of Interest Form
Please wait... 
  
If this message is not eventually replaced by the proper contents of the document, your PDF 
viewer may not be able to display this type of document. 
  
You can upgrade to the latest version of Adobe Reader for Windows®, Mac, or Linux® by 
visiting  http://www.adobe.com/go/reader_download. 
  
For more assistance with Adobe Reader visit  http://www.adobe.com/go/acrreader. 
  
Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark 
of Apple Inc., registered in the United States and other countries. Linux is the registered trademark of Linus Torvalds in the U.S. and other 
countries.
ICMJE Conflict of Interest Form
Please wait... 
  
If this message is not eventually replaced by the proper contents of the document, your PDF 
viewer may not be able to display this type of document. 
  
You can upgrade to the latest version of Adobe Reader for Windows®, Mac, or Linux® by 
visiting  http://www.adobe.com/go/reader_download. 
  
For more assistance with Adobe Reader visit  http://www.adobe.com/go/acrreader. 
  
Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark 
of Apple Inc., registered in the United States and other countries. Linux is the registered trademark of Linus Torvalds in the U.S. and other 
countries.
ICMJE Conflict of Interest Form
Please wait... 
  
If this message is not eventually replaced by the proper contents of the document, your PDF 
viewer may not be able to display this type of document. 
  
You can upgrade to the latest version of Adobe Reader for Windows®, Mac, or Linux® by 
visiting  http://www.adobe.com/go/reader_download. 
  
For more assistance with Adobe Reader visit  http://www.adobe.com/go/acrreader. 
  
Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark 
of Apple Inc., registered in the United States and other countries. Linux is the registered trademark of Linus Torvalds in the U.S. and other 
countries.
ICMJE Conflict of Interest Form
Please wait... 
  
If this message is not eventually replaced by the proper contents of the document, your PDF 
viewer may not be able to display this type of document. 
  
You can upgrade to the latest version of Adobe Reader for Windows®, Mac, or Linux® by 
visiting  http://www.adobe.com/go/reader_download. 
  
For more assistance with Adobe Reader visit  http://www.adobe.com/go/acrreader. 
  
Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark 
of Apple Inc., registered in the United States and other countries. Linux is the registered trademark of Linus Torvalds in the U.S. and other 
countries.
ICMJE Conflict of Interest Form
Please wait... 
  
If this message is not eventually replaced by the proper contents of the document, your PDF 
viewer may not be able to display this type of document. 
  
You can upgrade to the latest version of Adobe Reader for Windows®, Mac, or Linux® by 
visiting  http://www.adobe.com/go/reader_download. 
  
For more assistance with Adobe Reader visit  http://www.adobe.com/go/acrreader. 
  
Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark 
of Apple Inc., registered in the United States and other countries. Linux is the registered trademark of Linus Torvalds in the U.S. and other 
countries.
ICMJE Conflict of Interest Form
Please wait... 
  
If this message is not eventually replaced by the proper contents of the document, your PDF 
viewer may not be able to display this type of document. 
  
You can upgrade to the latest version of Adobe Reader for Windows®, Mac, or Linux® by 
visiting  http://www.adobe.com/go/reader_download. 
  
For more assistance with Adobe Reader visit  http://www.adobe.com/go/acrreader. 
  
Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark 
of Apple Inc., registered in the United States and other countries. Linux is the registered trademark of Linus Torvalds in the U.S. and other 
countries.
ICMJE Conflict of Interest Form
Please wait... 
  
If this message is not eventually replaced by the proper contents of the document, your PDF 
viewer may not be able to display this type of document. 
  
You can upgrade to the latest version of Adobe Reader for Windows®, Mac, or Linux® by 
visiting  http://www.adobe.com/go/reader_download. 
  
For more assistance with Adobe Reader visit  http://www.adobe.com/go/acrreader. 
  
Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark 
of Apple Inc., registered in the United States and other countries. Linux is the registered trademark of Linus Torvalds in the U.S. and other 
countries.
ICMJE Conflict of Interest Form
Please wait... 
  
If this message is not eventually replaced by the proper contents of the document, your PDF 
viewer may not be able to display this type of document. 
  
You can upgrade to the latest version of Adobe Reader for Windows®, Mac, or Linux® by 
visiting  http://www.adobe.com/go/reader_download. 
  
For more assistance with Adobe Reader visit  http://www.adobe.com/go/acrreader. 
  
Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark 
of Apple Inc., registered in the United States and other countries. Linux is the registered trademark of Linus Torvalds in the U.S. and other 
countries.
ICMJE Conflict of Interest Form
